Evidence map›Paper›PMID 40546817›Full record

ArticleTherapeutic advances in hematology2025

Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab.

Jan Philipp Bewersdorf, Vanessa Hasle, Rory M Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac Boss, Lourdes Mendez, Nikolai Podoltsev, Maximilian Stahl and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jan Philipp BewersdorfSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.ORCID https://orcid.org/0000-0003-3352-0902
Vanessa HasleBristol Myers Squibb, Princeton, NJ, USA.
Rory M ShallisSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.ORCID https://orcid.org/0000-0002-8542-2944
Ethan ThompsonBristol Myers Squibb, Princeton, NJ, USA.
Daniel Lopes de MenezesBristol Myers Squibb, Princeton, NJ, USA.
Shelonitda RoseBristol Myers Squibb, Princeton, NJ, USA.
Isaac BossBristol Myers Squibb, Princeton, NJ, USA.
Lourdes MendezSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
Nikolai PodoltsevSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
Maximilian StahlDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Tariq KewanSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
Stephanie HaleneSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Brian A FoxBristol Myers Squibb, Princeton, NJ, USA.
Amer M ZeidanSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USA.ORCID https://orcid.org/0000-0001-7017-8160

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: RNA splicing factor (SF) mutations are associated with adverse outcomes in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes/neoplasms (HR-MDS). Preclinical data suggest that aberrant RNA splicing can lead to the generation of neoantigens, which renders these tumors more susceptible to immune checkpoint inhibitors. However, dedicated studies on immune checkpoint inhibitors in AML and MDS patients with SF mutations are limited. Objectives: To characterize the immune and epigenetic landscape of AML and MDS patients with SF mutations. Design: Post hoc analysis of the impact of RNA SF mutations (defined as any of Methods: Primary endpoint was the overall response rate (ORR). Flow cytometry and gene expression profiling using bulk RNA sequencing were performed on pretreatment bone marrow aspirate samples. Results: One hundred twenty-six patients with AML (51 SF-mutant and 75 wild type) and 79 patients with MDS (33 SF-mutant and 46 wild type) were included. ORR was independent of SF mutation status for both AML (SF-mutant: 35.3% vs wild-type: 33.3%; Conclusion: Addition of durvalumab to azacitidine did not improve ORR or OS among older patients with newly diagnosed AML and HR-MDS independent of SF mutation status.

Indexed as

AMLgene expressionimmune phenotypeMDSoutcomessplicing mutation

Identifiers

PMID40546817
PMCPMC12182606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.